Watch Ticker

Erasca, Inc. Common Stock

Go to Erasca, Inc. Common Stock Website

$1.48

-0.02 (-1.33%)

Live

Previous Close

$1.5

Day Range

$0 - $0

Previous Day Range

$1.38 - $1.51

Market Cap

$396.6 million USD

Day Vol.

Previous Day Vol.

911203

Currency

USD

Primary Exchange

Nasdaq

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF ...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Na - Erasca to Present at Upcoming Investor Conferences in June

Erasca, a clinical-stage precision oncology company, announced the advancement of its RAS-targeting franchise, with IND clearance for ERAS-0015 and IND submission for ERAS-4001, both ahead of schedule. The company expects to report Phase 1 monotherapy data for both programs in 2026 and has a projected cash runway of more than 3 years.

Related tickers: ERAS.

Read Full Article

N/A - Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Erasca, Inc. (ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced its participation in the Guggenheim Securities SMID Cap Biotech Conference, where management will present and hold one-on-one investor meetings.

Related tickers: ERAS.

Read Full Article

Trending Tickers

Please sign in to view